Syndication: The Gleaner
(New Brunswick, NJ/77WABC)-A 3rd potential vaccine to fight Covid-19 is on-the-horizon. NJ based, Johnson & Johnson, headquartered in New Brunswick, NJ, https://www.jnj.com, has submitted paperwork to the Food and Drug Administration seeking approval of its single-dose Covid-19 vaccine following Clinical Trials.
According to early findings resulting from a study of 44,000 people in the U.S., Latin America and South Africa, the single-dose vaccine was 66% effective at preventing moderate to severe COVID-19. Researchers found Johnson & Johnson’s Covid-19 vaccine was 85% protective against Covid-19’s most serious symptoms. After 28 days, none of those who received the J & J vaccine needed hospitalization or died as a result of Covid-19.
BREAKING: Johnson & Johnson says it has asked U.S. regulators to OK its one-shot COVID-19 vaccine. https://t.co/sm6o2rhy7D
— The Associated Press (@AP) February 4, 2021
The single-dose option worked better in the U.S. – 72% effective against moderate to severe COVID-19 – compared with 66% in Latin America and 57% in South Africa, where a more contagious mutant variant of the virus is spreading. https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
Clinical trials of the Pfizer and Moderna Covid-19 vaccines, which require two doses, showed the vaccines to be 95% effective in fighting COVID-19 related symptoms.
